Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 2, 2016, Pages 97-104

  Lau, George ^a,b   Benhamou, Yves ^c   Chen, Guofeng ^b   Li, Jin ^b   Shao, Qing ^b   Ji, Dong ^b   Li, Fan ^b   Li, Bing ^b   Liu, Jialiang ^b   Hou, Jinlin ^d   Sun, Jian ^d   Wang, Cheng ^a,d   Chen, Jing ^a   Wu, Vanessa ^a   Wong, April ^a   Wong, Chris L P ^e   Tsang, Stella T Y ^e   Wang, Yudong ^a   Bassit, Leda ^f   Tao, Sijia ^f   Jiang, Yong ^f   Hsiao, Hui Mien ^f   Ke, Ruian ^g,h   Perelson, Alan S ^g   Schinazi, Raymond F ^f   more..

^a Humanity and Health Medical Centre   (China)

^b BEIJING 302 HOSPITAL   (China)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e Hong Kong Bioinformatics Centre   (China)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LOS ALAMOS NATIONAL LABORATORY   (United States)

^h NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; DACLATASVIR; LEDIPASVIR; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BMS-790052; FLUORENE DERIVATIVE; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MIDDLE AGED; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; FOLLOW UP; INTENTION TO TREAT ANALYSIS; ORAL DRUG ADMINISTRATION; PROOF OF CONCEPT; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTENTION TO TREAT ANALYSIS; ISOQUINOLINES; MALE; MIDDLE AGED; PROOF OF CONCEPT STUDY; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84995756438     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30015-2     Document Type: Article

References (34)

1. 1 AASLD–IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD–IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
2. 2 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
3. 3 Afdhal, N, Zeuzem, S, Kwo, P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
4. 4 Afdhal, N, Reddy, KR, Nelson, DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
5. 5 Kowdley, KV, Gordon, SC, Reddy, KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
6. 6 Sulkowski, MS, Gardiner, DF, Rodriguez-Torres, M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370 (2014), 211–221.
7. 7 Jayasekera, CR, Barry, M, Roberts, LR, Nguyen, MH, Treating hepatitis C in lower-income countries. N Engl J Med 370 (2014), 1869–1871.
8. 8 McCarthy, M, Fake medicines are undermining global efforts to combat infectious disease, says US journal. BMJ, 350, 2015, h2137.
9. 9 Attaran, A, Stopping murder by medicine: introducing the Model Law on Medicine Crime. Am J Trop Med Hyg 92:6 suppl (2015), 127–132.
10. 10 Hagan, LM, Sulkowski, MS, Schinazi, RF, Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 60 (2014), 37–45.
11. 11 Hill, A, Khoo, S, Fortunak, J, Simmons, B, Ford, N, Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 58 (2014), 928–936.
12. 12 Gane, EJ, Stedman, CA, Hyland, RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 146 (2014), 736–743.
13. 13 Kohli, A, Osinusi, A, Sims, Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 385 (2015), 1107–1113.
14. 14 Perelson, AS, Guedj, J, Modelling hepatitis C therapy—predicting effects of treatment. Nat Rev Gastroenterol Hepatol 12 (2015), 437–445.
15. 15 Guedj, J, Dahari, H, Shudo, E, Smith, P, Perelson, AS, Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatolgy 55 (2012), 1030–1037.
16. 16 Guedj, J, Pang, PS, Denning, J, et al. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther 19 (2014), 211–220.
17. 17 Guedj, J, Perelson, AS, Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 53 (2011), 1801–1808.
18. 18 Messina, JP, Humphreys, I, Flaxman, A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
19. 19 Liu, CH, Kao, JH, Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomed 9 (2014), 2051–2067.
20. 20 Kai, Y, Hikita, H, Tatsumi, T, et al. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. J Gastroenterol 50 (2015), 1145–1151.
21. 21 Sulkowski, M, Hezode, C, Gerstoft, J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2015), 1087–1097.
22. 22 Guedj, J, Dahari, H, Rong, L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 110 (2013), 3991–3996.
23. 23 Rong, L, Guedj, J, Dahari, H, et al. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol, 9, 2013, e1002959.
24. 24 Kumada, H, Suzuki, Y, Ikeda, K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59 (2014), 2083–2091.
25. 25 Omata, M, Kanda, T, Wei, L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Intl, 2016, 10.1007/s12072-016-9717-6 published online April 29.
26. 26 Poordad, F, Lawitz, E, Gutierrez, JA, et al. C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks. J Hepatol 62 (2015), S192–S193.
27. 27 Kattakuzhy, S, Sidharthan, S, Wilson, E, et al. Predictors of sustained viral response to 4–6 week duration therapy with ledipasvir + sofosbuvir + GS-9451 +/− GS-9669 in early and advanced fibrosis (NIH/UMD synergy trial). J Hepatol, 62, 2015, S669.
28. 28 Lawitz, EJ, Gruener, D, Hill, JM, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 57 (2012), 24–31.
29. 29 Svarovskaia, ES, Dvory-Sobol, H, Parkin, N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 59 (2014), 1666–1674.
30. 30 Swallow, E, Kelley, C, Signorovitch, J, Wygant, G, McPhee, F, Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. J Comp Eff Res 5 (2016), 273–279.
31. 31 Snoeck, E, Chanu, P, Lavielle, M, et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 87 (2010), 706–713.
32. 32 Reig, M, Marino, Z, Perello, C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol, 2016, 10.1016/j.jhep.2016.04.008 published online April 12.
33. 33 Nguyen, LH, Nguyen, MH, Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 37 (2013), 921–936.
34. 34 Wei, L, Lopez-Talavera, J, Roa, H, et al. Prevalence of HCV viral and host IL28B genotypes in China. Hepatology 54 (2011), 563A–5664.